{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:30:48Z","timestamp":1787009448429,"version":"build-2736575974"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T00:00:00Z","timestamp":1633651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Candida endophthalmitis is a serious complication of candidemia. Diagnosis requires identification of ocular lesions on dilated fundoscopy, aided by isolation of the organism from blood and\/or vitreous humor. However, the initial ophthalmological examination may be negative in some cases. Experience with isavuconazole for the treatment of Candida endophthalmitis is limited. We present a case of a 65-year-old woman with metastatic breast cancer on chemotherapy who developed Candida dubliniensis endophthalmitis with initial negative ophthalmological examination. She was treated with vitrectomy and 6 weeks of oral fluconazole. Despite vitrectomy and culture-directed antifungal treatment, management was complicated by lack of response to fluconazole and intolerance to other antifungals, necessitating the use of isavuconazole, which proved efficacious.<\/jats:p>","DOI":"10.1093\/ofid\/ofab516","type":"journal-article","created":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T21:20:48Z","timestamp":1633728048000},"source":"Crossref","is-referenced-by-count":9,"title":["<i>Candida<\/i>\n                    Endophthalmitis Treated Successfully With Isavuconazole: A Case Report"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6522-2614","authenticated-orcid":false,"given":"Edwin Chong Yu","family":"Sng","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Singapore General Hospital, Singapore, Singapore"},{"name":"Department of Infectious Diseases, Changi General Hospital, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai Ling","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Singapore General Hospital, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peijun Yvonne","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Singapore General Hospital, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tira J","family":"Tan","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, National Cancer Centre, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samanthila","family":"Waduthantri","sequence":"additional","affiliation":[{"name":"Singapore National Eye Centre, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soon-Phaik","family":"Chee","sequence":"additional","affiliation":[{"name":"Singapore National Eye Centre, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1458-9456","authenticated-orcid":false,"given":"Ban Hock","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Singapore General Hospital, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,10,8]]},"reference":[{"key":"2021121102234872300_CIT0001","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/cid\/cir355","article-title":"Ocular manifestations of candidemia.","volume":"53","author":"Oude Lashof","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2021121102234872300_CIT0002","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jamaophthalmol.2019.0733","article-title":"Utility of ophthalmologic screening for patients with Candida bloodstream infections: a systematic review.","volume":"137","author":"Breazzano","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"2021121102234872300_CIT0003","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jinf.2020.12.032","article-title":"Endogenous Candida endophthalmitis: who is really at risk?","volume":"82","author":"Seidelman","year":"2021","journal-title":"J Infect"},{"key":"2021121102234872300_CIT0004","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ajo.2011.06.020","article-title":"Endogenous fungal endophthalmitis: causative organisms, management strategies, and visual acuity outcomes.","volume":"153","author":"Lingappan","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"2021121102234872300_CIT0005","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1097\/IAE.0b013e31822d3a34","article-title":"Factors determining visual outcome in endogenous Candida endophthalmitis.","volume":"32","author":"Sallam","year":"2012","journal-title":"Retina"},{"key":"2021121102234872300_CIT0006","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2021121102234872300_CIT0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2021.07.015","article-title":"American Academy of Ophthalmology recommendations on screening for endogenous Candida endophthalmitis.","author":"Breazzano","year":"2021","journal-title":"Ophthalmology"},{"key":"2021121102234872300_CIT0008","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.diagmicrobio.2017.02.014","article-title":"No evidence of increased ocular involvement in candidemic patients initially treated with echinocandins.","volume":"88","author":"Mu\u00f1oz","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2021121102234872300_CIT0009","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1128\/CMR.00046-13","article-title":"Tissue penetration of antifungal agents.","volume":"27","author":"Felton","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"2021121102234872300_CIT0010","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1086\/431761","article-title":"Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis.","volume":"41","author":"Gauthier","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2021121102234872300_CIT0011","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1086\/427753","article-title":"Candida glabrata endophthalmitis treated successfully with caspofungin.","volume":"40","author":"Sarria","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2021121102234872300_CIT0012","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/cid\/ciq204","article-title":"Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents.","volume":"52","author":"Riddell","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2021121102234872300_CIT0013","doi-asserted-by":"crossref","first-page":"379A","DOI":"10.1111\/j.1469-0691.1997.tb00269.x","article-title":"Intravitreous penetration of fluconazole during endophthalmitis.","volume":"3","author":"Tod","year":"1997","journal-title":"Clin Microbiol Infect"},{"key":"2021121102234872300_CIT0014","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/archopht.122.1.42","article-title":"Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans.","volume":"122","author":"Hariprasad","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"2021121102234872300_CIT0015","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1136\/bjo.2007.136515","article-title":"Voriconazole in the treatment of fungal eye infections: a review of current literature.","volume":"92","author":"Hariprasad","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"2021121102234872300_CIT0016","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1128\/AAC.46.12.3719-3723.2002","article-title":"Ocular distribution of intravenously administered lipid formulations of amphotericin B in a rabbit model.","volume":"46","author":"Goldblum","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2021121102234872300_CIT0017","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"2021121102234872300_CIT0018","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1093\/cid\/ciy827","article-title":"Isavuconazole versus caspofungin in the treatment of candidemia and other invasive candida infections: The ACTIVE Trial.","volume":"68","author":"Kullberg","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021121102234872300_CIT0019","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/mmy\/myz103","article-title":"Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system.","volume":"58","author":"Schwartz","year":"2020","journal-title":"Med Mycol"},{"key":"2021121102234872300_CIT0020","doi-asserted-by":"crossref","first-page":"e01292-17","DOI":"10.1128\/AAC.01292-17","article-title":"Tissue distribution and elimination of isavuconazole following single and repeat oral-dose administration of isavuconazonium sulfate to rats.","volume":"61","author":"Schmitt-Hoffmann","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2021121102234872300_CIT0021","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/myc.12731","article-title":"Isavuconazole shortens the QTc interval.","volume":"61","author":"Mellinghoff","year":"2018","journal-title":"Mycoses"},{"key":"2021121102234872300_CIT0022","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3390\/jof6040324","article-title":"Isavuconazole: mechanism of action, clinical efficacy, and resistance.","volume":"6","author":"Ellsworth","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"2021121102234872300_CIT0023","volume-title":"Sensititre YeastOne Susceptibility Plates [product information] [029-Yeast-ROW IVD CID10305]","year":"2019"},{"key":"2021121102234872300_CIT0024","volume-title":"MIC Test Strip Technical Sheet Yeast [product information] [MTS24, Rev. 5.2]","year":"2016"},{"key":"2021121102234872300_CIT0025","volume-title":"Performance Standards for Antifungal Susceptibility Testing of Yeasts","author":"CLSI.","year":"2020"},{"key":"2021121102234872300_CIT0026","volume-title":"Epidemiological Cutoff Values for Antifungal Susceptibility Testing","author":"CLSI.","year":"2020"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofab516\/40533102\/ofab516.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/8\/12\/ofab516\/41722409\/ofab516.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/8\/12\/ofab516\/41722409\/ofab516.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T22:49:13Z","timestamp":1639176553000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofab516\/6384660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,8]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofab516","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,1]]},"published":{"date-parts":[[2021,10,8]]},"article-number":"ofab516"}}